The Novosibirsk researchers have developed a vaccine that is able to cause both humoral and cellular immunity, it means that under the influence of this vaccine, activated cells of the immune system will both form virus antibodies and devour the cells infected by the virus.
The vaccine per se is an artificial virus-like particle. Its capsule consists of the TBI (T- and B cell epitopes containing immunogen) protein constructed by the researchers, the TBI protein being combined with the polyglucin protein. This protein contains 9 participants stimulating different cells of the immune system – both the ones that produce antibodies and the ones that devour the newcomer. The DNA coding the TCI (T-cell immunogen) protein is contained inside the protein coat. The protein contains more than 80 HIV proteins fragments selected in the optimal way, which should activate the immune system.
The researchers have selected only conservative fragments, i.e. the ones that remain constant in the course of all major changes of HIV-1 and will certainly be noticed by the immunize organism. As a matter of fact, the coat and the filling of the particle represent independent vaccines, which cause specific cellular and humoral immune response. In the assembled form, the combiHiVvac vaccine is a particle 40 to 100 nanometers in diameter, approaching in size to the HIV-1 virus.
The antibodies, which are formed by immunized mice under the action of vaccine, recognize the real HIV-1 proteins and neutralize the virus. This was shown by the experiments on the cell culture infected by the virus and processed by mice’s antibodies. Preclinical trial findings allow to hope that the combiHIVvac vaccine will fight efficiently even against modified HIV-1 variants.
The new vaccine is nontoxic. Its single injection to mice even in the fivefold dose does not cause derangements to the organs, and repeated injections reinforce inflammatory processes in the liver, but only in the case if the liver is already out of order. The combiHIVvac vaccine does not cause autoimmune diseases or anaphylactic reactions, it does not weaken the organism’s tolerance to infections either.
The scientists emphasize that as the combiHIVvac vaccine not only stimulates antibody production but also destroys the cells infected by the virus, this vaccine can be considered not only a prophylactic one but also as a therapeutic one. In the Novosibirsk researchers’ opinion, the vaccine they developed is ready for clinical trials.
Nadezda Markina | alfa
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences